Controversy: Anticoagulants need to be maintained after catheter ablation of atrial fibrillation in patients at risk of stroke—Pro and Contra
Europace · 02.11.2026
DOI: 10.1093/europace/euag311 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Europace, online erschienen am 02.11.2026. Verfasst von Giuseppe Boriani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, …. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Anticoagulants, Stroke. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
The pillars of atrial fibrillation (AF) management include stroke prevention, patient-centred symptom directed decisions on rhythm or rate control, and the proactive management of comorbidities and lifestyle changes. These pillars are not in isolation; they are complementary to each other. While oral anticoagulants (OACs) are highly effective for reducing stroke and all-cause mortality in patients with AF, these drugs confer a risk of major bleeding, including intracranial bleeding. Evidence from clinical trials and observational data shows that early rhythm control, especially with catheter ablation, results in a reduction in stroke risk and/or the reduction in AF burden. The question arises therefore, whether in patients with intermediate or low stroke risk after successful catheter ablation, whether or not to continue or discontinue OAC. Recent randomized trials and observational data have created some debate about whether OAC can be routinely stopped after a successful catheter ablation procedure, without a higher risk of thromboembolism. In this pro/contra article, we will debate the arguments for and against the cessation of anti-coagulation after catheter ablation, in the context of recent evidence from clinical trials, observational data, and meta-analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
- Division of Cardiology, Clinic Pasteur, Toulouse, France.
- Department of Cardiology, Centre Hospitalier Universitaire Trousseau, Faculté de Médecine, INSERM UMR1327 ISCHEMIA, Tours, France.
- Department of Cardiology, Université François Rabelais, Tours, France.
- Institute of Health Informatics Research, University College London, London, United Kingdom.
ORCID-Profile: Giuseppe Boriani, Serge Boveda, Davide A Mei, Laurent Fauchier, Jacopo F Imberti, Rui Providencia, Gregory Y H Lip
Zitieren
APA
Boriani, G., Boveda, S., Mei, D. A., Fauchier, L., Imberti, J. F., Providencia, R., & Lip, G. Y. H. (2026). Controversy: Anticoagulants need to be maintained after catheter ablation of atrial fibrillation in patients at risk of stroke—Pro and Contra. Europace. https://doi.org/10.1093/europace/euag311
Vancouver
Boriani G, Boveda S, Mei DA, Fauchier L, Imberti JF, Providencia R, et al. Controversy: Anticoagulants need to be maintained after catheter ablation of atrial fibrillation in patients at risk of stroke—Pro and Contra. Europace. 2026. doi:10.1093/europace/euag311
BibTeX
@article{Boriani2026,
author = {Boriani, Giuseppe and Boveda, Serge and Mei, Davide A and Fauchier, Laurent and Imberti, Jacopo F and Providencia, Rui and Lip, Gregory Y H},
title = {Controversy: Anticoagulants need to be maintained after catheter ablation of atrial fibrillation in patients at risk of stroke—Pro and Contra},
journal = {Europace},
year = {2026},
doi = {10.1093/europace/euag311}
}
EUVIMED